Efficacy and Safety of a Formulated Herbal Granula, Jiu Wei Zhen Xin, for Generalized Anxiety Disorder: A Meta-Analysis

Table 1

Details of the included trials for JWZXG in the treatment of GAD.

Study	Men/total	Age	Diagnostic criteria	Therapy duration	Interventions		Response definition	Method	Jadad scores	Dropout rate
					T	C
Guo et al., 2012	T 29/50; C 26/50	T 40.8 ± 13.2; C 43.2 ± 14.3	CCMD-3; HAMA ≥ 14	6 w	JWZX; 18 g/d	Buspirone; 15–60 mg/d	HAMA, TESS,; response rate	Randomization, blinding of experimenter, participants, and assessors (placebo)	3	NR
Liang, 2012	T 18/40; C 19/40	T 40.5 ± 11.4; C 41.0 ± 10.9	CCMD-3; HAMA > 14	6 w	JWZX; 18 g/d	Sertraline; 50–100 mg/d	HAMA, TESS,; response rate	Randomization	1	NR
Liang, 2014	T 22/54; C 20/53	T 36.5 ± 4.3; C 35.6 ± 4.2	CCMD-3; HAMA ≥ 14	6 w	JWZX; 18 g/d	Paroxetine; 10–40 mg/d	HAMA, TESS,; response rate	Randomization (random digit table), dropouts	3	T 2; C 3
Liu, 2013	T 13/32; C 15/35	T 37.7 ± 8.6; C 38.7 ± 9.1	ICD-10; HAMA ≥ 14	6 w	JWZX; 18 g/d	Buspirone; 15–30 mg/d	HAMA, TESS,; response rate	Randomization, dropouts	2	T 5; C 6
Wang et al., 2013	T 140/336; C 41/111	T 42 ± 14; C 43 ± 13	CCMD-3; HAMA ≥ 14	4 w	JWZX; 24.1 ± 4.0 g/d	Buspirone; 24.5 ± 4.3 mg/d	HAMA, TESS,; response rate	Randomization (random digit table), dropouts, blinding of experimenter, participants, and assessors (placebo)	5	T 22/337; C 6/111
Wu et al., 2012	T 12/30; C 14/30	T 31.5 ± 15.5; C 33.5 ± 13.2	CCMD-3; HAMA ≥ 14; SAS ≥ 50	6 w	JWZX; 18 g/d	Tandospirone; 30 mg/d	HAMA, SAS, TESS; response rate	Randomization, blinding of assessors	1	NR
Wu and Wang, 2012	32/68	34.4 ± 4.9	ICD-10; HAMA ≥ 14; SAS ≥ 50	8 w	JWZX; 18 g/d	Sertraline; 50 mg/d	HAMA, TESS	Randomization	1	NR
Yang et al., 2013	T 14/36; C 13/36	T 33.5 ± 11.8; C 32.5 ± 12.1	CCMD-3; HAMA ≥ 14	8 w	JWZX; 18 g/d	Tandospirone; 15–60 mg/d	HAMA, TESS,; response rate	Randomization	1	NR
Zhang et al., 2012a	T 22/40; C 21/40	T 42.2 ± 15.5; C 42.7 ± 15.0	CCMD-3	6 w	JWZX; 18 g/d	Buspirone; 15–60 mg/d	HAMA, TESS, response rate	Randomization, blinding of assessors	1	NR
Zhang et al., 2012b	T 14/30; C 15/30	T 38.4 ± 13.7; C 38.9 ± 12.9	CCMD-3; HAMA ≥ 14	6 w	JWZX; 18 g/d	Paroxetine; 20 mg/d	HAMA, CGI,; response rate	Randomization, dropouts, blinding of assessors	2	T 2; C 2
Pan et al., 2016	T 12/30; C 15/30	T 36 ± 7.1; C 39.1 ± 9.6	CCMD-3	4 W	JWZX; 18 g/d	Tandospirone; 15–30 mg/d	HAMA,; response rate	Randomization, blinding of assessors	3	NR
Ren et al., 2015	T 12/36; C 11/36	T 34.6 ± 15.2; C 35.2 ± 13.9	CCMD-3	6 W	JWZX; 18 g/d	Paroxetine; 10–40 mg/d	HAMA, TESS,; response rate	Randomization, dropouts	4	T 3/36; C 4/36
Ren and Hu, 2015	NR	T 43.2 ± 6.7; C 42.4 ± 9.3	CCMD-3	6 W	JWZX; 18 g/d	Escitalopram 5–15 mg/d	HAMA,; response rate	Randomization	1	NR
Ji, 2015	T 19/32; C 18/33	T 36.2 ± 11.4; C 38.5 ± 12.8	CCMD-3	6 W	JWZX; 18 g/d	Tandospirone; 15–60 mg/d	HAMA, TESS,; response rate	Randomization, dropouts	1	T 2; C 3

GAD: generalized anxiety disorder; JWZXG: Jiu Wei Zhen Xin Granula; CCMD-3: Chinese Classification of Mental Disorders, Third Edition; ICD-10: International Classification of Diseases Tenth Revision; HAMA: Hamilton Anxiety Rating Scale; SAS: Self-Rating Anxiety Scale; TESS: Treatment Emergent Symptom Scale; NR: not reported; T: treatment group; C: control group.